Alterity Therapeutics Proposes Massive Option Grant to Chairman and Executive, Signaling Extreme Potential Dilution

summarizeSummary

Alterity Therapeutics proposes issuing 150 million options to its Chairman and another executive as compensation, which, if approved and exercised, could lead to over 800% dilution based on current market capitalization.

check_boxKey Events

• Proposed Option Grant

  The company proposes to issue 150,000,000 options to its Chairman, Julian Babarczy, and Lawrence Gozlan.

• Compensation for Services

  These options are intended as payment for services rendered, with no cash consideration provided for the options themselves.

• Low Exercise Price

  Each option has an exercise price of A$0.02 and an expiry date of June 26, 2031.

• Significant Potential Dilution

  If all options are exercised, the number of outstanding shares would increase substantially, potentially leading to over 800% dilution based on the current market capitalization.

auto_awesomeAnalysis

Alterity Therapeutics has proposed a highly dilutive option grant of 150 million options to its Chairman, Julian Babarczy, and Lawrence Gozlan as compensation for services rendered. These options have a low exercise price of A$0.02 and, if approved by shareholders and subsequently exercised, would significantly increase the company's outstanding share count. Based on the current market capitalization and stock price, the potential issuance of 150 million shares could result in over 800% dilution, representing a substantial transfer of value and a major concern for existing shareholders. The proposal requires shareholder approval, highlighting the importance of the upcoming vote.